OM
MCID: OTT002
MIFTS: 68

Otitis Media (OM)

Categories: Ear diseases, Genetic diseases

Aliases & Classifications for Otitis Media

MalaCards integrated aliases for Otitis Media:

Name: Otitis Media 57 12 75 29 55 3 44 15 73
Otitis Media, Susceptibility to 57 13 6
Otitis Media, Chronic/recurrent 57 75
Come/rom 57 75
Oms 57 75
Infectious Otitis Media 73
Om 75

Characteristics:

OMIM:

57
Inheritance:
familial predisposition


HPO:

32
otitis media:
Inheritance polygenic inheritance


Classifications:



External Ids:

OMIM 57 166760
Disease Ontology 12 DOID:10754
ICD10 33 H66.9 H66.90
ICD9CM 35 382.9
MeSH 44 D010033
NCIt 50 C34885
SNOMED-CT 68 65363002
MedGen 42 C1833692

Summaries for Otitis Media

UniProtKB/Swiss-Prot : 75 Otitis media: An inflammation of the middle ear resulting in earache, fever, hearing disturbance, and vertigo.

MalaCards based summary : Otitis Media, also known as otitis media, susceptibility to, is related to suppurative otitis media and haemophilus influenzae. An important gene associated with Otitis Media is A2ML1 (Alpha-2-Macroglobulin Like 1), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Cedax and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include bone, tonsil and colon, and related phenotypes are recurrent otitis media and hematopoietic system

Disease Ontology : 12 A otitis which involves inflammation of the middle ear.

Wikipedia : 76 Otitis media is a group of inflammatory diseases of the middle ear. The two main types are acute otitis... more...

Description from OMIM: 166760

Related Diseases for Otitis Media

Diseases related to Otitis Media via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 520)
# Related Disease Score Top Affiliating Genes
1 suppurative otitis media 34.5 IL1B TLR2 TLR4
2 haemophilus influenzae 31.3 CXCL8 IL1B TLR2 TNF
3 tonsillitis 30.7 CD79A CXCL8 IL1B IL6 TNF
4 septic arthritis 30.7 CXCL8 TLR2 TLR4
5 rhinitis 30.7 CCL11 CXCL8 IGHE RNASE3
6 mycobacterium fortuitum 30.5 CXCL8 LACTB
7 mycobacterium abscessus 30.5 CXCL8 TLR2 TNF
8 meningitis 30.5 TNF TLR2 MBL2 LACTB IL6 IL1B
9 mycobacterium chelonae 30.5 CXCL8 TLR2
10 arthritis 30.5 CXCL8 IL10 IL1B IL6 TNF
11 ige responsiveness, atopic 30.4 IGHE IL10 RNASE3
12 allergic rhinitis 30.4 CCL11 CXCL8 IGHE IL10 RNASE3
13 paraneoplastic syndromes 30.3 IL1B IL6
14 milk allergy 30.3 CD79A IL10 RNASE3
15 osteomyelitis 30.3 CXCL8 IL10 IL1B IL6 TNF
16 conjunctivitis 30.2 CCL11 CXCL8 IL6 RNASE3
17 fasciitis 30.2 CXCL8 IL6 TNF
18 common cold 30.1 CCL11 CXCL8 MUC5AC RNASE3
19 churg-strauss syndrome 30.1 IL10 RNASE3 TNF
20 bacterial meningitis 30.0 TNF TLR2 IL6 IL1B IL10 CXCL8
21 monocytic leukemia 30.0 CXCL8 IL1B IL6 TNF
22 aseptic meningitis 30.0 CXCL8 IL10 IL1B TNF
23 sleep apnea 30.0 CXCL8 IL1B IL6 TNF
24 cytomegalovirus infection 30.0 CXCL8 IL1B IL6 TNF
25 bacterial sepsis 30.0 CXCL8 IL10 TLR4 TNF
26 lyme disease 29.9 IL1B IL6 TLR2 TNF
27 chorioamnionitis 29.9 CXCL8 IL1B IL6 TLR4 TNF
28 acquired immunodeficiency syndrome 29.9 IL10 IL1B IL6 TNF
29 middle ear disease 29.9 TNF TLR4 TLR2 MUC5B MUC5AC IL6
30 lymphadenitis 29.9 CXCL8 IL10 IL1B TLR4 TNF
31 appendicitis 29.9 CXCL8 IL10 IL1B IL6 TNF
32 bone inflammation disease 29.8 CXCL8 IL10 IL1B IL6 TNF
33 keratoconjunctivitis 29.8 CCL11 CXCL8 RNASE3 TNF
34 viral infectious disease 29.8 CXCL8 IL10 IL1B IL6 TNF
35 extrapulmonary tuberculosis 29.8 IL10 IL1B MBL2 TLR2
36 pulmonary tuberculosis 29.8 IL10 MBL2 TLR2 TNF
37 keratoconjunctivitis sicca 29.8 CD79A IL10 IL1B IL6 TNF
38 bronchitis 29.7 CCL11 CXCL8 LACTB RNASE3 TNF
39 respiratory allergy 29.7 CCL11 IGHE IL10 RNASE3
40 listeriosis 29.7 IL6 MBL2 TNF
41 peritonitis 29.7 TNF TLR2 IL6 IL1B IL10 CXCL8
42 asthma 29.7 TNF TLR4 RNASE3 MUC5AC IL6 IL1B
43 bronchiolitis 29.5 TNF TLR4 RNASE3 MUC5B IL6 IL10
44 pneumonia 29.5 TNF TLR4 TLR2 MUC5B MBL2 LACTB
45 pulmonary disease, chronic obstructive 29.4 TNF TLR2 RNASE3 MUC5AC IL6 CXCL8
46 chlamydia 29.3 TNF TLR4 TLR2 IL6 IL1B IL10
47 inflammatory bowel disease 28.9 CCL11 CXCL8 IL10 IL1B IL6 MUC2
48 acute serous otitis media 12.8
49 chronic purulent otitis media 12.8
50 non-suppurative otitis media 12.8

Comorbidity relations with Otitis Media via Phenotypic Disease Network (PDN): (show all 11)


Acute Cystitis Bronchitis
Cholesteatoma of Middle Ear Chronic Myocardial Ischemia
Deficiency Anemia Heart Disease
Hypertension, Essential Labyrinthitis
Mastoiditis Otitis Externa
Pneumococcal Meningitis

Graphical network of the top 20 diseases related to Otitis Media:



Diseases related to Otitis Media

Symptoms & Phenotypes for Otitis Media

Symptoms via clinical synopsis from OMIM:

57
Ears:
susceptibility to otitis media


Clinical features from OMIM:

166760

Human phenotypes related to Otitis Media:

32
# Description HPO Frequency HPO Source Accession
1 recurrent otitis media 32 HP:0000403

MGI Mouse Phenotypes related to Otitis Media:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL11 CD79A IL10 IL1B IL6 MBL2
2 homeostasis/metabolism MP:0005376 9.93 CD79A FBXO11 IL10 IL1B IL6 MBL2
3 digestive/alimentary MP:0005381 9.92 FBXO11 IL10 IL6 MUC2 MUC5AC TLR2
4 immune system MP:0005387 9.77 CCL11 CD79A FBXO11 IL10 IL1B IL6
5 neoplasm MP:0002006 9.23 CD79A IL10 IL1B IL6 MUC2 TLR2

Drugs & Therapeutics for Otitis Media

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cedax 18 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995

Drugs for Otitis Media (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Halofantrine Approved Phase 4 69756-53-2 37393
3
Montelukast Approved Phase 4,Phase 3,Not Applicable 158966-92-8 5281040
4 Strawberry Approved Phase 4
5
Lansoprazole Approved, Investigational Phase 4,Not Applicable 103577-45-3 3883
6
Dexlansoprazole Approved, Investigational Phase 4,Not Applicable 103577-45-3, 138530-94-6 9578005
7
Azithromycin Approved Phase 4,Phase 3,Phase 2 83905-01-5 55185 447043
8
Cefdinir Approved Phase 4,Phase 2,Phase 3 91832-40-5 6915944
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Oseltamivir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 204255-11-8, 196618-13-0 65028
12
Ibuprofen Approved Phase 4,Not Applicable 15687-27-1 3672
13
Acetaminophen Approved Phase 4,Phase 2,Not Applicable 103-90-2 1983
14
Histamine Approved, Investigational Phase 4,Phase 3,Not Applicable 51-45-6, 75614-87-8 774
15
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 1177-87-3
17
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 85721-33-1 2764
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
19
Levofloxacin Approved, Investigational Phase 4,Phase 3 100986-85-4 149096
20
Ofloxacin Approved Phase 4,Phase 3 82419-36-1 4583
21
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
22
Phenylephrine Approved Phase 4,Not Applicable 59-42-7 6041
23
Oxymetazoline Approved, Investigational Phase 4,Not Applicable 1491-59-4 4636
24
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
25
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
26
Cetirizine Approved Phase 4 83881-51-0 2678
27
Methylprednisolone Approved, Vet_approved Phase 4,Early Phase 1 83-43-2 6741
28
Methylprednisolone hemisuccinate Approved Phase 4,Early Phase 1 2921-57-5
29
Prednisolone Approved, Vet_approved Phase 4,Early Phase 1 50-24-8 5755
30
Prednisolone phosphate Approved, Vet_approved Phase 4,Early Phase 1 302-25-0
31
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
33
BCG vaccine Investigational Phase 4
34 Andrographolide Investigational Phase 4 5508-58-7
35
Prednisolone hemisuccinate Experimental Phase 4,Early Phase 1 2920-86-7
36 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Amoxicillin-Potassium Clavulanate Combination Phase 4,Phase 3,Phase 2
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Clavulanic Acids Phase 4,Phase 3,Phase 2,Not Applicable
40 beta-Lactamase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
42 Anti-Asthmatic Agents Phase 4,Not Applicable
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
44 Leukotriene Antagonists Phase 4,Not Applicable
45 Respiratory System Agents Phase 4,Not Applicable
46 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
47 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
48 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
50 Anesthetics, General Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 322)
# Name Status NCT ID Phase Drugs
1 Amoxicillin Clavulanate in Treatment of Acute Otitis Media Unknown status NCT00299455 Phase 4 amoxicillin-clavulanate;Placebo
2 The Influence of The Ear Popper on Serous Otitis Media and on the Accompanying Conductive Hearing Loss in Children Unknown status NCT00393159 Phase 4
3 Acute Otitis Media (AOM) Therapy Trial in Young Children Completed NCT00377260 Phase 4 amoxicillin-clavulanate;Placebo
4 A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children Completed NCT00189462 Phase 4 Montelukast
5 Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children Completed NCT00539149 Phase 4 Amoxycillin;Placebo equivalent to amoxycillin
6 Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children Completed NCT01082029 Phase 4 Lansoprazole;Placebo
7 A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media Completed NCT00645112 Phase 4 cefdinir (Omnicef);azithromycin
8 A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media Completed NCT00644943 Phase 4 cefdinir (Omnicef);amoxicillin
9 Pneumococcal Vaccines Early and in Combination Completed NCT01174849 Phase 4 Synflorix;Prevenar13;COMBO
10 Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy Completed NCT01244126 Phase 4 Intranasal fentanyl;morphine IM;IV morphine
11 Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®) Completed NCT00419380 Phase 4 dornase alfa (Pulmozyme®)
12 Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age Completed NCT00593502 Phase 4 oseltamivir;placebo
13 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. Completed NCT01694108 Phase 4
14 Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics) Completed NCT01800747 Phase 4
15 DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect Completed NCT00424905 Phase 4 Bacillus clausii
16 Hutterite Influenza Prevention Study Completed NCT00877396 Phase 4
17 A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age Completed NCT00946101 Phase 4
18 A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults Completed NCT00945893 Phase 4
19 Live Versus Inactivated Influenza Vaccine Study in Hutterite Children Completed NCT01653015 Phase 4
20 Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza Completed NCT01804946 Phase 4 Ergoferon;Oseltamivir
21 Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children Recruiting NCT02935374 Phase 4 Amoxicillin;Amoxicillin-Potassium Clavulanate;Macrolide
22 Ketorolac Sublingual vs. Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children Recruiting NCT02653742 Phase 4 Ketorolac;Fentanyl
23 Group A Pharyngitis in Children: The GASPARD Study Recruiting NCT03264911 Phase 4 Amoxicillin or Placebo
24 A Study of Andrographolide Sulfonate in Patients With Acute Exacerbation of Chronic Bronchitis Recruiting NCT03132610 Phase 4 andrographolide sulfonate;andrographolide sulfonate simulation
25 Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Tonsillitis Recruiting NCT03134443 Phase 4 Andrographolide sulfonate;Andrographolide sulfonate simulation
26 The Benefit and Harm of Fever Suppression by Antipyretics in Influenza Recruiting NCT01891084 Phase 4 Paracetamol;Placebo;Backup NSAID ibuprofen
27 Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life Active, not recruiting NCT01735084 Phase 4
28 Efficacy and Cost Analysis of Steroid Spray in Treatment of Otitis Media With Effusion Not yet recruiting NCT03590912 Phase 4 Fluticasone Nasal;Anti Histamine plus Nasal decongestents;Steroid Drug
29 N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Not yet recruiting NCT00956748 Phase 4 Ciprodex;Ciprodex and 2% NAC
30 Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present Not yet recruiting NCT03655665 Phase 4 Ofloxacin otic solution
31 A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain Terminated NCT01032837 Phase 4 Oseltamivir;Oseltamivir;Placebo
32 Otiprio Versus Ciprodex Tympanostomy Tube Outcomes Withdrawn NCT03347461 Phase 4 Otiprio;Ciprodex
33 A Comparative Study of the Outcomes of 2 Surgical Procedures for Safe Type of Chronic Otitis Media Unknown status NCT00271778 Phase 3
34 PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers to See if it Protects Their Babies From Ear Disease Unknown status NCT00310349 Phase 3
35 Preventing Early Childhood Caries in Indigenous Children: the Baby Teeth Talk Study Unknown status NCT02151916 Phase 3
36 Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Unknown status NCT01619462 Phase 3
37 Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children Completed NCT01044030 Phase 3 Xylitol syrup;Placebo
38 Improving Otitis Media Care With Clinical Decision Support Completed NCT00581711 Phase 3
39 Sinuclean Nebules 45 for Treatment of Pediatric Exudative Otitis Media Completed NCT02858388 Phase 3
40 Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence Completed NCT02345447 Phase 3 Herbal-based medication;Placebo
41 Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes Completed NCT02600559 Phase 3 OTO-201 (ciprofloxacin)
42 Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children Completed NCT00781521 Phase 3 ofloxacin otic solution 0.3%
43 A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes Completed NCT00578474 Phase 3 Moxidex otic solution;Ofloxacin otic solution
44 Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children Completed NCT02541760 Phase 3 Monteleukast;Mometasone
45 Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media Completed NCT00638534 Phase 3 Telithromycin (HMR3647)
46 Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media Completed NCT02044341 Phase 3 AR01;Glycerin ear drops
47 Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes Completed NCT00378417 Phase 3
48 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) Completed NCT02432105 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
49 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2 Completed NCT02436304 Phase 3 EXE844 Sterile Otic Suspension, 0.3%
50 Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes Completed NCT00579189 Phase 3 Moxidex otic solution;Moxifloxacin otic solution

Search NIH Clinical Center for Otitis Media

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: otitis media

Genetic Tests for Otitis Media

Genetic tests related to Otitis Media:

# Genetic test Affiliating Genes
1 Otitis Media 29

Anatomical Context for Otitis Media

MalaCards organs/tissues related to Otitis Media:

41
Bone, Tonsil, Colon, Testes, Neutrophil, Brain, Lung

Publications for Otitis Media

Articles related to Otitis Media:

(show top 50) (show all 2528)
# Title Authors Year
1
A mixed-methods study of the management of hearing loss associated with otitis media with effusion in children with Down syndrome. ( 30222906 )
2019
2
The use of bone conduction hearing implants in paediatric chronic otitis media: An audit of outcomes of 32 devices in 22 patients. ( 30270554 )
2019
3
Diagnostic Accuracy, Prescription Behavior, and Watchful Waiting Efficacy for Pediatric Acute Otitis Media. ( 30311779 )
2019
4
Studying PCV impact on clinical presentation of otitis media helps to understand its pathogenesis. ( 30497832 )
2019
5
The Value of Diffusion-Weighted MRI in the Long-term follow-up After Subtotal Petrosectomy for Extensive Cholesteatoma and Chronic Suppurative Otitis Media. ( 30531639 )
2019
6
Surgery for Chronic Otitis Media Causes Greater Taste Disturbance Than Surgery for Otosclerosis. ( 30540698 )
2019
7
Apigetrin treatment attenuates LPS-induced acute otitis media though suppressing inflammation and oxidative stress. ( 30551453 )
2019
8
Probiotics in the treatment of otitis media. The past, the present and the future. ( 30554684 )
2019
9
Characteristics of children with refractory acute otitis media treated at the pediatric emergency department. ( 30554692 )
2019
10
Clinical role of vitamin D in prognosis of otitis media with effusion. ( 29447793 )
2018
11
Risk factors of sensorineural hearing loss in patients with unilateral safe chronic suppurative otitis media. ( 29331307 )
2018
12
To Evaluate and Compare the Result of Ossiculoplasty Using Different Types of Graft Materials and Prosthesis in Cases of Ossicular Discontinuity in Chronic Suppurative Otitis Media Cases. ( 29456937 )
2018
13
In vivo detection of nanometer-scale structural changes of the human tympanic membrane in otitis media. ( 29884809 )
2018
14
Otitis Media with Effusion (OME) in Urban Pediatric Population in a Tertiary Care Centre: A Clinical Study. ( 29977853 )
2018
15
A pilot study to investigate the therapeutic effect of Valsalva maneuver on otitis media with effusion in adults. ( 29914826 )
2018
16
Effect of esterified hyaluronic acid as middle ear packing in tympanoplasty for adhesive otitis media. ( 29073815 )
2018
17
Use of Streptococcus salivarius K12 to reduce the incidence pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects. ( 29322750 )
2018
18
The Role of Mannose-Binding Lectin Serum Level in Tubotympanic Chronic Suppurative Otitis Media. ( 29951099 )
2018
19
Air Pollution and Otitis Media in Children: A Systematic Review of Literature. ( 29401661 )
2018
20
Ambulatory Visits for Otitis Media before and after the Introduction of Pneumococcal Conjugate Vaccination. ( 29958675 )
2018
21
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. ( 29885746 )
2018
22
No evidence of cholesteatoma in untreated otitis media with effusion in children with primary ciliary dyskinesia. ( 29447810 )
2018
23
Response to comment: Eustachian tube diameter: Is it associated with chronic otitis media development? ( 29426733 )
2018
24
Group A streptococcus acute otitis media progressing to neuroinvasive disease in adults. ( 29942780 )
2018
25
Efficacy of Boric Acid as a Treatment of Choice for Chronic Suppurative Otitis Media and Its Ototoxicity. ( 29383205 )
2018
26
Pneumococcal phenotype and interaction with nontypeable<i>Haemophilus influenzae</i>as determinants of otitis media progression. ( 29378791 )
2018
27
The anti-inflammatory effects of erythromycin, clarithromycin, azithromycin and roxithromycin on histamine-induced otitis media with effusion in guinea pigs. ( 29888693 )
2018
28
The Allele 2 of the VNTR Polymorphism in the Gene That Encodes a Natural Inhibitor of IL-1I^, IL-1RA Is Favorably Associated With Chronic Otitis Media. ( 29433161 )
2018
29
International consensus (ICON) on management of otitis media with effusion in children. ( 29398506 )
2018
30
Fungal Suppurative Otitis Media (Histopathology) Among Patients in North India. ( 29671212 )
2018
31
Risk of childhood otitis media with focus on potentially modifiable factors: A Danish follow-up cohort study. ( 29447878 )
2018
32
Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control. ( 29415741 )
2018
33
Development of an ear cap in chronic suppurative otitis media using additive manufacturing and TRIZ. ( 29916767 )
2018
34
Air pollution influences the incidence of otitis media in children: A national population-based study. ( 29953484 )
2018
35
Anatomical anomalies of the Eustachian tube and chronic otitis media. ( 29395282 )
2018
36
Optimal control of asthma improved eosinophilic otitis media. ( 29423372 )
2018
37
Tympanostomy tubes for serous otitis media and risk of recurrences. ( 29447881 )
2018
38
The Impact of Clinical Pathways on Antibiotic Prescribing for Acute Otitis Media and Pharyngitis in the Emergency Department. ( 29561517 )
2018
39
Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab. ( 29909018 )
2018
40
Meningitis as a consequence of otitis media in a child referred from the newborn hearing screening programme: A missed opportunity. ( 29427298 )
2018
41
Loss of the homeostatic protein BPIFA1, leads to exacerbation of otitis media severity in the Junbo mouse model. ( 29449589 )
2018
42
Aerobic bacteria associated with chronic suppurative otitis media in Angola. ( 29720274 )
2018
43
Influence of Vitamin D Deficiency on Progression of Experimental Otitis Media in Rats. ( 29947185 )
2018
44
Efficacy of Empirical Therapy With Combined Ciprofloxacin Versus Topical Drops Alone in Patients With Tubotympanic Chronic Suppurative Otitis Media: A Randomized Double-Blind Controlled Trial. ( 29348711 )
2018
45
Shewanella algae in a chronic suppurative otitis media patient with cholesteatoma. ( 29681564 )
2018
46
Prevalence of otitis media and risk-factors for sensorineural hearing loss among infants attending Child Welfare Clinics in the Solomon Islands. ( 29958609 )
2018
47
Genetic counseling in an indigenous Filipino community with a high prevalence of A2ML1-related otitis media. ( 29949068 )
2018
48
Neurological Complications of Acute and Chronic Otitis Media. ( 29445883 )
2018
49
Intracochlear Pressures in Simulated Otitis Media With Effusion: A Temporal Bone Study. ( 29912830 )
2018
50
Innovative Use of Tympanometry and Scintigraphy in Preoperative Assessment of the Patients with Chronic Otitis Media. ( 29977845 )
2018

Variations for Otitis Media

ClinVar genetic disease variations for Otitis Media:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 A2ML1 NM_144670.5(A2ML1): c.2478_2485dupGGCTAAAT (p.Ser829Trpfs) duplication Pathogenic,risk factor rs863224951 GRCh37 Chromosome 12, 9004820: 9004827
2 A2ML1 NM_144670.5(A2ML1): c.2478_2485dupGGCTAAAT (p.Ser829Trpfs) duplication Pathogenic,risk factor rs863224951 GRCh38 Chromosome 12, 8852224: 8852231

Expression for Otitis Media

LifeMap Discovery
Genes differentially expressed in tissues of Otitis Media patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PNLIPRP3 pancreatic lipase-related protein 3 Blood - 6.47 0.003
2 FAM20A family with sequence similarity 20, member A Blood + 3.09 0.015
Search GEO for disease gene expression data for Otitis Media.

Pathways for Otitis Media

Pathways related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 CCL11 CD79A CXCL8 IGHE IL10 IL1B
2
Show member pathways
13.44 CCL11 CXCL8 IL10 IL1B IL6 TLR2
3
Show member pathways
13.37 CCL11 CXCL8 IGHE IL10 IL1B IL6
4
Show member pathways
13.07 CXCL8 IL1B IL6 TLR2 TLR4 TNF
5
Show member pathways
13.05 CXCL8 IL10 IL1B IL6 MBL2 TLR2
6
Show member pathways
12.92 CCL11 CXCL8 IL10 IL1B IL6 RNASE3
7
Show member pathways
12.83 CXCL8 IL1B IL6 TLR2 TLR4 TNF
8
Show member pathways
12.78 CXCL8 IL1B IL6 TLR4 TNF
9
Show member pathways
12.72 IL1B IL6 TLR2 TLR4 TNF
10
Show member pathways
12.64 IL10 IL1B IL6 TLR2 TLR4 TNF
11 12.6 CD79A IL10 IL1B TLR2 TNF
12
Show member pathways
12.43 IL1B MUC2 MUC5AC MUC5B
13
Show member pathways
12.43 IL10 IL1B IL6 TNF
14
Show member pathways
12.36 CXCL8 IL1B IL6 TLR4 TNF
15
Show member pathways
12.32 CXCL8 IL6 TLR2 TLR4 TNF
16
Show member pathways
12.31 IL10 IL1B TLR2 TLR4 TNF
17
Show member pathways
12.3 CXCL8 IL10 IL1B IL6 TNF
18 12.29 IL10 IL1B IL6 TLR2 TLR4 TNF
19
Show member pathways
12.26 CCL11 CXCL8 IL1B IL6 MUC5AC MUC5B
20
Show member pathways
12.24 IL10 IL1B IL6 TNF
21 12.23 CXCL8 IL10 IL1B IL6 TNF
22 12.22 IL6 TLR2 TLR4 TNF
23
Show member pathways
12.22 CCL11 CXCL8 IL1B IL6 TLR2 TLR4
24
Show member pathways
12.12 IL10 IL1B IL6 TLR2 TLR4 TNF
25
Show member pathways
12.11 CCL11 CXCL8 IL10 IL1B IL6
26
Show member pathways
12.1 IL1B IL6 TLR2 TLR4 TNF
27 12.08 CXCL8 IL1B IL6 TLR4 TNF
28 12.04 CD79A IL10 IL6 TNF
29
Show member pathways
12 CXCL8 IL1B IL6 MUC2 MUC5AC MUC5B
30 11.96 CXCL8 IL1B IL6 TNF
31 11.94 CXCL8 IL1B TLR4 TNF
32 11.91 CXCL8 IL1B IL6 TLR2 TLR4 TNF
33 11.89 CXCL8 IL1B IL6 TLR4
34
Show member pathways
11.87 CXCL8 IL6 TLR4
35 11.86 CCL11 CXCL8 IGHE IL10 IL1B IL6
36 11.82 IL10 IL1B IL6 TNF
37 11.79 IL10 IL1B TNF
38 11.79 CCL11 IL10 IL1B IL6 TNF
39 11.79 CXCL8 IL10 IL1B IL6 TLR4 TNF
40
Show member pathways
11.72 CXCL8 IL1B IL6 TNF
41 11.68 CCL11 IGHE IL10
42 11.68 CCL11 CXCL8 IL1B IL6 MUC5B TNF
43 11.6 CXCL8 IL10 IL1B IL6 TNF
44 11.59 IL1B TLR2 TLR4 TNF
45 11.59 CXCL8 IL1B IL6 TLR2 TLR4 TNF
46 11.54 CCL11 CXCL8 IL6
47 11.52 IL1B IL6 TNF
48 11.44 IL10 IL1B IL6 TLR4 TNF
49 11.43 IL10 IL1B IL6 TNF
50 11.36 IL1B IL6 TNF

GO Terms for Otitis Media

Cellular components related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 A2ML1 CCL11 CXCL8 IGHE IL10 IL1B
2 extracellular space GO:0005615 9.36 A2ML1 CCL11 CXCL8 IL10 IL1B IL6

Biological processes related to Otitis Media according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.97 IGHE IL10 MBL2 RNASE3 TLR4 TNF
2 response to lipopolysaccharide GO:0032496 9.96 IL10 IL1B TLR2 TLR4
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 IL1B IL6 TLR2 TLR4 TNF
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.91 IL10 IL1B IL6 TNF
5 defense response to Gram-negative bacterium GO:0050829 9.89 IL6 RNASE3 TLR4
6 neutrophil chemotaxis GO:0030593 9.88 CCL11 CXCL8 IL1B
7 positive regulation of JNK cascade GO:0046330 9.88 IL1B TLR4 TNF
8 positive regulation of inflammatory response GO:0050729 9.87 TLR2 TLR4 TNF
9 response to glucocorticoid GO:0051384 9.87 IL10 IL1B IL6 TNF
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.85 MUC2 MUC5AC MUC5B
11 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IL10 IL1B IL6 TLR4 TNF
12 O-glycan processing GO:0016266 9.84 MUC2 MUC5AC MUC5B
13 defense response to Gram-positive bacterium GO:0050830 9.83 IL6 MBL2 RNASE3 TLR2 TNF
14 positive regulation of interferon-gamma production GO:0032729 9.82 IL1B TLR4 TNF
15 positive regulation of nitric oxide biosynthetic process GO:0045429 9.82 IL1B TLR4 TNF
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.81 IL1B TLR2 TLR4 TNF
17 positive regulation of phagocytosis GO:0050766 9.8 IL1B MBL2 TNF
18 cytokine-mediated signaling pathway GO:0019221 9.8 CCL11 CXCL8 IGHE IL10 IL1B IL6
19 negative regulation of interleukin-6 production GO:0032715 9.78 IL10 TLR4 TNF
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 IL1B TLR2 TLR4 TNF
21 negative regulation of neurogenesis GO:0050768 9.77 IL1B IL6 TNF
22 positive regulation of glial cell proliferation GO:0060252 9.75 IL1B IL6 TNF
23 negative regulation of growth of symbiont in host GO:0044130 9.73 IL10 MBL2 TNF
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.72 IL10 IL1B TNF
25 regulation of cytokine secretion GO:0050707 9.71 TLR2 TLR4
26 I-kappaB phosphorylation GO:0007252 9.71 TLR2 TLR4
27 response to molecule of bacterial origin GO:0002237 9.71 CXCL8 IL10 TLR2
28 positive regulation of interleukin-8 production GO:0032757 9.71 IL1B TLR2 TLR4 TNF
29 cellular response to lipoteichoic acid GO:0071223 9.7 TLR2 TLR4
30 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.69 TLR4 TNF
31 negative regulation of lipid storage GO:0010888 9.69 IL6 TNF
32 endothelial cell apoptotic process GO:0072577 9.69 IL10 TNF
33 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL1B TNF
34 positive regulation of MHC class II biosynthetic process GO:0045348 9.67 IL10 TLR4
35 regulation of establishment of endothelial barrier GO:1903140 9.67 IL1B TNF
36 negative regulation of cytokine secretion involved in immune response GO:0002740 9.66 IL10 TNF
37 positive regulation of fever generation GO:0031622 9.65 IL1B TNF
38 chronic inflammatory response to antigenic stimulus GO:0002439 9.64 IL1B TNF
39 sequestering of triglyceride GO:0030730 9.63 IL1B TNF
40 positive regulation of neuroinflammatory response GO:0150078 9.63 IL1B IL6 TNF
41 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.62 IL1B TNF
42 receptor biosynthetic process GO:0032800 9.62 IL10 TNF
43 positive regulation of chemokine production GO:0032722 9.62 IL6 TLR2 TLR4 TNF
44 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.6 TLR2 TLR4
45 inflammatory response GO:0006954 9.56 CCL11 CXCL8 IL10 IL1B IL6 TLR2
46 positive regulation of interleukin-6 production GO:0032755 9.55 IL1B IL6 TLR2 TLR4 TNF
47 immune response GO:0006955 9.28 CCL11 CXCL8 IGHE IL10 IL1B IL6
48 positive regulation of transcription by RNA polymerase II GO:0045944 10.22 IL10 IL1B IL6 SHOX TLR2 TLR4
49 innate immune response GO:0045087 10.11 IGHE MBL2 RNASE3 TLR2 TLR4
50 negative regulation of cell proliferation GO:0008285 10.08 CXCL8 IL10 IL1B IL6 TLR2

Molecular functions related to Otitis Media according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4
2 lipopolysaccharide binding GO:0001530 9.13 RNASE3 TLR2 TLR4
3 cytokine activity GO:0005125 9.1 CCL11 CXCL8 IL10 IL1B IL6 TNF

Sources for Otitis Media

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....